Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Nuclear receptor subfamily 1 group I member 2 (NR1I2), widely known as the Pregnane X receptor (PXR) or Steroid and xenobiotic receptor (SXR), is a key transcription factor that functions as a chemical sensor for the body [1.4.1, 1.4.3]. It is predominantly expressed in the liver and gastrointestinal tract, where it detects a broad range of exogenous xenobiotics and endogenous compounds like bile acids [1.2.3, 1.3.4]. When activated by a ligand, PXR heterodimerizes with the Retinoid X receptor (RXR) to upregulate genes involved in all phases of drug metabolism and transport, most notably the cytochrome P450 3A4 (CYP3A4) enzyme [1.1.1, 1.4.1]. This protective mechanism facilitates the detoxification and elimination of potentially harmful substances [1.2.1, 1.3.3]. However, PXR activation is also the primary molecular basis for many significant drug-drug interactions, as it can lead to the rapid clearance of other therapeutic agents [1.3.1, 1.3.2]. Additionally, PXR plays a role in metabolic homeostasis and inflammation, making it a target of interest for treating conditions such as cholestasis and inflammatory bowel disease [1.3.4, 1.4.4].
PXR acts as a ligand-activated transcription factor that, upon binding to a variety of hydrophobic compounds, forms a heterodimer with the Retinoid X receptor (RXR) [1.4.1]. This complex binds to specific DNA response elements (e.g., DR3, ER6) in the promoter regions of target genes, inducing the expression of Phase I enzymes (CYP3A4, CYP2B6), Phase II enzymes (UGTs, SULTs), and Phase III transporters (MDR1, MRP2) [1.2.3, 1.3.4]. This coordinated induction enhances the detoxification and clearance of xenobiotics and endobiotics [1.3.1].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear receptor subfamily 1 group I member 2 (NR1I2) (PXR).